Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARG-007 in acute ischemic stroke undergoing endovascular revascularization
ACTRN12623001110673Phase 2Completed
- Sponsor
- Argenica Therapeutics Limited
- Start
- Mar 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in ischemic stroke comparing ARG-007 with Saline placebo (2 arms). Primary endpoint: Safety of a single dose of ARG-007 in acute ischemic stroke. Started Mar 2024; status: completed.
02
Drugs
ARG-007
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ACTRN12623001110673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001110673.